Related Experiment Video
Updated: Mar 18, 2026
High-throughput Fluorometric Measurement of Potential Soil Extracellular Enzyme Activities
Published on: November 15, 2013
[Not Available]
Pauline Gerritsen-van Schieveen1, Bernard Royer2,
1CHU Besançon, Laboratoire de Pharmacologie Clinique, Hôpital Jean Minjoz, Besançon, France.
Abstract:
Mycophenolic acid (MPA) is more and more used to prevent GVHD (Graft Versus Host Disease) during hematopoietic stem cell transplantation with reduce-intensity conditioning. If several facts argue in favor of therapeutic drug monitoring, the used pharmacokinetic parameter is to be defined. Especially, the choice between total or ultrafilterable MPA is still under debate even if therapeutic drug monitoring seems to be more practicable with total MPA. The role of other factors implied in GVHD occurrence are also to be assessed in studies which aim at assessing therapeutic drug monitoring of MPA in such situation. For theses reasons, the level evidence of MPA as GVHD prophylaxis during hematopoietic stem cell transplantation with reduce-intensity conditioning is potentially useful.
Insights
Therapeutic drug monitoring of mycophenolic acid (MPA) aids in preventing Graft Versus Host Disease (GVHD) after stem cell transplants. Defining the best pharmacokinetic parameter, like total MPA, is crucial for effective monitoring in reduce-intensity conditioning regimens.
Area of Science:
- Pharmacology
- Immunology
- Hematology
Context:
- Mycophenolic acid (MPA) is increasingly utilized for Graft Versus Host Disease (GVHD) prophylaxis in hematopoietic stem cell transplantation (HSCT) using reduce-intensity conditioning.
- The need for therapeutic drug monitoring (TDM) of MPA is supported by growing evidence.
- Optimal pharmacokinetic parameters for MPA TDM in this context require further definition.
Purpose:
- To evaluate the evidence supporting the use of MPA for GVHD prophylaxis in HSCT with reduce-intensity conditioning.
- To discuss the choice of pharmacokinetic parameters for MPA TDM, specifically total versus ultrafilterable MPA.
- To highlight the need for further studies assessing MPA TDM and other factors influencing GVHD.
Summary:
- MPA is a key agent for preventing GVHD in HSCT, but TDM is essential for optimizing its use.
- The debate continues regarding whether total or ultrafilterable MPA is the superior pharmacokinetic parameter for TDM, though total MPA appears more practical.
- Further research is needed to clarify the role of MPA TDM and other contributing factors in GVHD occurrence.
Impact:
- This review provides a comprehensive overview of the current evidence for MPA in GVHD prophylaxis.
- It guides clinicians in selecting appropriate pharmacokinetic parameters for MPA TDM, potentially improving patient outcomes.
- Identifies research gaps and future directions for optimizing MPA-based GVHD prevention strategies in HSCT.
